Compounded vs Branded GLP-1
Compounded GLP-1s are prepared by licensed compounding pharmacies and frequently allow dosing flexibility (microdose ramp, custom titration) at lower cost. Branded GLP-1s are FDA-approved manufactured products with the largest clinical trial evidence base. Both pathways require provider review; the comparison is regulatory and operational, not pharmacologic at the molecule level.
Compounded GLP-1 is appropriate when dosing flexibility (microdose entry, custom titration), cost, or supply considerations matter — under full provider review and using only licensed compounding pharmacies.
Branded GLP-1 is appropriate when insurance access, manufacturer-trial alignment, or the fixed-pen pathway match the patient's context.
Educational. Final pathway selection is provider-reviewed via synchronous video consultation against your biomarkers, history, and goals.
Frequently asked
Are compounded GLP-1s the same molecule as branded?
When sourced from licensed compounding pharmacies, yes — the active pharmaceutical ingredient is the same. The regulatory pathway and finished-product approval differ.
Is compounded GLP-1 still allowed if the branded shortage ends?
Compounding rules are tied to FDA shortage status and the specific molecule. The provider review accounts for current regulatory state at the time of prescribing.
Take the optimization assessment.
The adaptive assessment maps your symptoms, history, and goals to candidate pathways — and routes you into provider review.
Begin assessment